Trials / Completed
CompletedNCT00421213
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Alaunos Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Darinaparsin | 300mg/m2 of Darinaparsin given daily for five consecutive days to be repeated every 28 days for up to six months. |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2007-01-11
- Last updated
- 2012-07-19
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00421213. Inclusion in this directory is not an endorsement.